Abstract: A method is provided for cationically polymerizing olefin monomer by employing the step of using a novel coinitiator in an organic phase or a neat monomer reaction phase. More specifically, a method is provided for cationically polymerizing olefin monomer by employing the step of using a novel coinitiator in an organic phase or a neat monomer reaction phase, wherein the organic phase is a hydrocarbon solution of the monomer or a halogenated-hydrocarbon solution of the monomer and wherein the neat-monomer reaction phase is a liquid monomer.

Abstract: Process for free-radical polymerization in the presence of a regulator which, following free-radical H-abstraction to form an aromatic system, eliminates a free-radical leaving group which starts a new free-radical chain.

Abstract: A non crosslinked, covalently crosslinked and/or ionically crosslinked polymer, having repeating units of the general formula (1) —K—R—??(1) In which K is a bond, oxygen, sulphur, the radical R is a divalent radical of an aromatic or heteroaromatic compound.

Abstract: The invention relates to a modified Ziegler catalyst for preparing a poly-1-olefin in suspension, in solution or in the gas phase, which catalyst comprises the reaction product of a magnesium alkoxide (component a) with a transition metal compound (component b) and an organometallic compound (component c) together with an additional component (d) comprising a compound of the chemical formula M?Rx where M is an element of main group IV of the Periodic Table, R is halogen or an organic radical such as alkyl having from 1 to 10 carbon atoms, oxyalkyl having from 1 to 10 carbon atoms, cycloalkyl having from 4 to 8 carbon atoms in the ring and, if desired, from 1 to 6 substituents R? on the ring, aryl having from 6 to 10 carbon atoms in the aromatic and, if desired, from 1 to 6 substituents R? on the aromatic, where R? is a halogen or an alkyl radical having from 1 to 4 carbon atoms or an OH group or an NO2 group or an oxyalkyl radical having from 1 to 4 carbon atoms, and x is an integer from 1 to 4.

Abstract: The invention relates to a process for the preparation of equilibration products of organosiloxanes by rearrangement of the siloxane bond to a cation exchange resin, the organopolysiloxanes thus obtainable and the use thereof.

Abstract: One embodiment of the invention is a composition adapted for coating goods comprising a polyisocyanate component and a polyisocyanate reactive component further comprising a polyaspartic ester and cycloaliphatic amine. Another embodiment of the invention is a method for coating goods by mixing a preferred polyisocyanate component with a preferred polyisocyanate reactive component and then applying the coating to the goods which are to be coated. Yet another embodiment of the invention is a method of adhering two surfaces by forming a coating by mixing a preferred polyisocyanate component with a preferred polyisocyanate reactive component, applying the coating mixture to one surface and contacting the second surface to the coated first surface.

Abstract: A process comprising: a) reacting a diphenol monomer A with a monomer B having two locations for reaction with A to form arylene ether monomer C and b) reacting arylene ether monomer C with a diphenol monomer D to form a polymer, where monomer A is HX1-Q1-X1H;??(II) monomer B is arylene ether monomer C is and monomer D is wherein: Q1 comprises at least one aryl or heteroaryl group; Q2 comprises at least one aryl or heteroaryl group; X1 is O bonded directly to an aryl carbon of Q1; X2 is O bonded directly to an aryl carbon of Q2; Z is a linker comprising at least one —(C(R2)2)— group; Y is a single bond or linker group (e.g., comprising up to about 50 carbons); R1 is independently at each occurrence H, a halogen, an alkyl group, a heteroalkyl group, an aryl group, or a heteroaryl group; R2 is independently at each occurrence H, an alkyl group, or a heteroalkyl group; and R3 is H or a crosslinkable group.

Abstract: A flexibilized resorcinolic novolak resin is prepared by reacting a phenolic compound, such as resorcinol, with an unsaturated dihydroxy, an unsaturated aldehyde, an aliphatic dialdehyde, or a mixture thereof. An aldehyde (different from the unsaturated aldehyde and the aliphatic dialdehyde) is either simultaneously or subsequently added to the reaction mixture. The flexibilized resorcinolic novolak resin can be used in an adhesive composition for enhancing the adhesion between tire cords and rubber for tire applications.

Abstract: Biodegradable aliphatic thermoplastic copolyesters of the saturated-unsaturated type, utilizable for the production of several types of articles such as films, sheets, nets, expanded molded products, and the like, and process for their production.

Abstract: A knitted/woven fabric of polyester fibers is produced from a polyester polymer obtained by condensation-polymerizing an aromatic dicarboxylate in the presence of a catalyst which comprises a mixture of a titanium compound ingredient (A) comprising a titanium alkoxide and at least one product of the reaction of the titanium alkoxide with a specific carboxylic acid or anhydride thereof and a specific phosphorus compound ingredient (B) and/or comprises a product of the reaction of a titanium compound ingredient (C) with a specific phosphorus compound ingredient (D). The knitted/woven fabric obtained has a satisfactory color tone (low value of b*) and is excellent in suitability for knitting/weaving and dyeability.

Abstract: A process for the production of polytrimethylene terephthalate (PTT), wherein the process comprises: (i) one or more esterification steps, wherein terephthalic acid (TPA) or an alkyl diester of terephthalic acid is reacted with 1,3-propanediol (PDO); and (ii) one or more subsequent polycondensation steps, wherein the process further comprises the addition of a protic acid, other than terephthalic or isophthalic acid, before and/or during the one or more esterification steps, wherein the protic acid has a dissociation constant of at most 4 (pKa measured in water at 25° C.), and wherein the total amount of protic acid added before and/or during the one or more esterification steps is in the range of from 0.001 to 10 millimole of acid per kilogram of polytrimethylene terephthalate produced.

Abstract: Cyclic oligomers containing ester linkages are polymerized in the presence of a catalyst having at least one oxygen atom bonded to two metal atoms. At least one of the metal atoms is a tin atom, which is preferably tetravalent, i.e., bonded to three other groups in addition to the oxygen atom. The other metal atom may also be another tin atom, which is again preferably tetravalent, or a zinc, aluminum or titanium atom. The catalyst may contain multiple oxygen atoms that are bonded to two such metal atoms as described. These catalysts are active, efficient polymerization catalysts. They are often liquids at polymerization temperatures. The catalysts can be formed in situ in the polymerization process, which provides additional flexibility in the process and increased storage stability of starting materials.

Abstract: This invention relates to cyclosporin derivatives of general formula (I): wherein A, B, R1, R2 and X are as defined in the specification, and pharmaceutical compositions prepared from the same, for use in treatment of hepatitis C virus.

Abstract: The invention provides inhibitors of matrix metalloproteinases that are useful for encouraging the development of healthy skin and for treating wounds. The inhibitors are peptides having sequences related to cleavage regions of the proenzyme forms of matrix metalloproteinases. The peptide inhibitors of the invention can be formulated into therapeutic compositions, lotions, creams, skin covering and wound dressings that facilitate healing and healthy skin development, discourage scarring and wrinkling and ameliorate the effects of healing.

Abstract: Provided are methods of identifying inhibitors of ?-secretase that employ modified ?-secretase substrates. The modified ?-secretase substrates have ?-secretase cleavage sites that are altered from wild type. The amino acid sequences of the altered ?-secretase cleavage sites contain different amino acids in at least one of the positions P2-P1-P1?-P2? of the ?-secretase cleavage site. Many of the modified ?-secretase substrates are more efficient substrates for ?-secretase than are corresponding substrates having wild-type sequences, that is, these modified substrates are more susceptible to enzymatic breakdown by ?-secretase. Recombinant polynucleotide molecules encoding the modified ?-secretase substrates are provided. Antibodies that recognize cleavage products of the modified ?-secretase substrates are provided. Stable cell lines expressing the modified ?-secretase substrates are provided. Transgenic animals expressing the modified ?-secretase substrates are provided.

Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The invention is directed to purified and isolated novel SVPH3-13 or SVPH3-17 polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.

Abstract: Isolated phosphorylated troponin I proteins useful in diagnosing and monitoring the phosphorylation state of injured muscle tissue are provided. Also provided are compounds, kits and methods for assessing the phosphorylation state of these troponin I proteins and modulating the phosphorylation state of these troponin I proteins in a subject.

Abstract: Provided herein are (a) Aiolos gene, Aiolos polypeptides, Aiolos homodimers, Aiolos/Ikaros heterodimers and methods of using Aiolos nucleic acids and polypeptides; (b) Helios gene, Helios polypeptides, Helios homodimers, Helios/Ikaros heterodimers, Helios/Aiolos heterodimers, and methods of using Helios nucleic acids and polypeptides; (c) Daedalos nucleic acids, Daedalos polypeptides, and other related molecules and methods of making and using the same; and (d) Ikaros regulatory elements and uses thereof.

Abstract: The present invention relates to a nucleic acid sequence linked to Alström syndrome, variants of that nucleic acid sequence, the protein produced by that nucleic acid sequence and screening methods for testing individuals to determine if they are carriers of Alström syndrome.

Abstract: Heterodimeric proteins comprising two helical bundle cytokines are disclosed. One of the polypeptides comprises zsig81 and a second polypeptide which comprises either p19 (aka IL-12A) or p35 (aka L-12A). The proteins may be produced as fusion proteins or expressed as a single chain. The heterdimeric protein comprising zsig81 and p19 is designated zcyto33f2 and the heterodimeric protein comprising zsig81 and p35 is designated zcyto35f2. Zcyto33f2 and zcyto35f2 proteins are associated with epithelial cell types, including lung and gut epithelium, and may play a role in physiological conditions such as inflammation.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: An antibody variable region of a monoclonal antibody specifically binding to human tumor necrosis factor-? contains at least one of a heavy chain variable region and a light chain variable region having specific complementarity determining regions therein. A nucleic acid molecule encoding the same, a recombinant vector containing the nucleic acid molecule, and a cell transformed with the recombinant vector are also provided.

Abstract: A gelatinizer having gel-forming capability in both organic solvents and water, is provided. The hydrogelatinizer is represented by: (where, A is a sugar residue, and R is an alkyl group).

Abstract: A method to manufacture calcium gluconolactate as a single molecule, compositions formed thereby, and uses therefor are disclosed and described. In one embodiment, a method of manufacturing calcium gluconolactate by reacting a gluconic acid reaction or an equivalent thereof, such as glucono delta lactone with lactic acid in the presence of calcium hydroxide and water to obtain a calcium gluconolactate molecule having the formula CH2OH—(CHOH)4—COOCaCOO—CH(OH)—CH3 with molecular weight of 324.2994 is presented.

Abstract: Methods for chemical modification of hyaluronic acid, formation of amine or aldehyde functionalized hyaluronic acid, and the cross-linking thereof to form hydrogels are provided. Functionalized hyaluronic acid hydrogels of this invention can be polymerized in situ, are biodegradable, and can serve as a tissue adhesive, a tissue separator, a drug delivery system, a matrix for cell cultures, and a temporary scaffold for tissue regeneration.

Abstract: Disclosed are DNA sequences encoding novel human thyroid peroxidase proteins and polypeptides capable of being secreted from cells, vectors comprising the sequences, and cells transformed with the vectors.

Abstract: The invention provides caspase recruitment domain (CARD)-containing polypeptides, CARD, NB-ARC, ANGIO-R, LRR and SAM domains therefrom, as well as encoding nucleic acid molecules and specific antibodies. The invention also provides related screening, diagnostic and therapeutic methods.

Abstract: The present invention relates to genomic nucleotide sequences and amino acid sequences corresponding to the non-coding and coding region of a new type of HCV. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes sequences. Particularly, the present invention relates to said new HCV type sequences; a process for preparing them, and their use for diagnosis, prophylaxis and therapy. More particularly, the present invention provides new type-specific sequences of the 5? NCR, Core, the E1 and the NS5 regions of the new HCV type. These new HCV sequences are useful to diagnose the presence of HCV type genotypes or serotypes in a biological sample. Moreover, the availability of these new type-specific sequences can increase the overall sensitivity of HCV detection and should also prove to be useful for prophylactic and therapeutic purposes.

Abstract: The present invention relates to the specific inhibition of expression of a fusion gene in mammals using a short double stranded RNA. The dsRNA is approximately 19–24 nucleotides in length, and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia.

Abstract: The present invention relates to a bovine VDJ cassette (BF1H1) that provides the novel ability to develop chimeric immunoglobulin molecule capable of incorporating both linear T cell epitope(s) (CDR1H and CDR2H) as well as conformational B cell epitope(s) (exceptionally long CDR3H). Further, multiple epitopes can be incorporated for development of multivalent vaccine by replacing at least a portion of an immunoglobulin molecule with the desired epitope such that functional ability of both epitope(s) and parent VDJ rearrangement is retained. The antigenized immunoglobulin incorporating both T and B epitopes of interest is especially useful for development of oral vaccines for use in humans apart from other species including cattle. The long CDR3H in BF1H1 VDJ rearrangement originates from long germline D-genes. The novel bovine germline D-genes provide unique molecular genetic marker for sustaining the D-gene pool in cattle essential for immunocompetence via selective breeding.

Abstract: A plasmid DNA that encodes one or more antigenic genes operably linked to a promoter and a truncated retroviral 3? LTR exhibits both enhanced safety and acceptable efficiency of expression of antigenic proteins.

Abstract: An expression library comprising a repertoire of nucleic acid sequences cloned from a non-immunised source, each nucleic acid sequence encoding at least part of a variable domain of a heavy chain derived from an immunoglobulin naturally devoid of light chains (VHH) wherein the extent of sequence variability in the library is enhanced compared to the corresponding naïve expression library by introducing mutations in one or more of the complementarity determining regions (CDRs) of the nucleic acid sequences or by generating alternative combinations of CDR and framework sequences not naturally present in the naïve library repertoire. Also disclosed is the use of such a library in preparing antibodies, more particularly antibody fragments.

Abstract: Human Borna disease virus (BDV) nucleic acids and polypeptides are described from three psychiatric patients. The human BDV-derived nucleic acids and polypeptides are useful in both DNA- and protein-based assays to detect human BDV in a subject, particularly the detection of BDV nucleic acids, BDV polypeptides and BDV antibodies generated in response to BDV infection.

Abstract: The invention provides variant regulator proteins of secondary metabolite production and nucleic acids encoding said variant regulator proteins. In particular, the invention provides variant regulator molecules of the lovE protein.

Abstract: The present invention relates to novel transcription control elements, including promoters, derived from angiogenesis-related genes, particularly the mouse VEGF gene, the mouse VEGFR-2 receptor gene, and the mouse Tie2 gene. Also disclosed are isolated polynucleotides comprising such promoters, as well as nucleic acid constructs comprising such promoters operatively linked to genes encoding a gene product, such as, a reporter, a protein, polypeptide, hormone, ribozyme, or antisense RNA, and to recombinant cells and transgenic animals comprising such nucleic acid constructs. The present invention further relates to screening methods using those recombinant cells and transgenic animals, particularly methods of screening for therapeutic compounds that modulate tumorigenesis and angiogenesis.

Abstract: The invention provides a catalytic, chemospecific and stereospecific method of oxidizing a wide variety of substrates without unwanted side reactions. Essentially, the method of the instant invention, under relatively mild reaction conditions, catalytically, stereospecifically and chemospecifically inserts oxygen into a hydrocarbon C—H bond. Oxidation (oxygen insertion) at a tertiary C—H bond to form an alcohol (and in some cases a hemiacetal) at the tertiary carbon is favored. The stereochemistry of an oxidized tertiary carbon is preserved. Ketones are formed by oxidizing a secondary C—H bond and ring-cleaved diones are formed by oxidizing cis tertiary CH bonds.

Abstract: Methods and materials involving 28-epirapamycin analogs are disclosed.

Abstract: A production method of 6-aminomethyl-6,11-dihydro-5H-dibenz[b,e]azepin characterized in that said compound is produced via N-[(6,11-dihydro-5H-dibenz[b,e]azepin-6-yl)methyl]-o-hydroxymethylbenzamide which is prepared by reducing 2-(11H-dibenz[b,e]azepin-6-ylmethyl)-1H-isoindole-1,3(2H)-dione employing a metal hydride or a metal hydride complex in a water based alcohol, and N-[(6,11-dihydro-5H-dibenz[b,e]azepin-6-yl)methyl]-o-hydroxymethylbenzamide which is useful for the aforesaid production method.

Abstract: A yellow dye-forming coupler represented by formula (I): wherein Q represents a group of nonmetallic atoms that form a 5- to 7-membered ring in combination with the —N?C—N(R1)—; R1 and R2 each represent a substituent; R4 represents an alkyl group; m represents an integer of 0 to 4; and X represents a hydrogen atom, or a group capable of being split-off upon a coupling reaction with an oxidized product of a developing agent; and when R4 represents a primary alkyl group, R1 represents —(CH2)3O—R101 in which R101 is an alkyl group having 4 to 8 carbon atoms. A silver halide color photographic light-sensitive material having at least one yellow dye-forming coupler represented by formula (I) in at least one layer provided on a support.

Abstract: The object of the present invention are new desloratadine salts of formula I wherein the meaning of X is an acid residue and the meaning of n is 1 or 2, and formula II wherein the meaning of X is a pK <3.5 acid residue.

Abstract: A process for the preparation of imidazo[1,2-a]-5,6,7,8-tetra hydropyridin-8-ones by reaction of ?-butyrolactones with imidazols, novel imidazo[1,2-a]-5,6,7,8-tetrahydropyridin-8-ones, and their use for the preparation of imidazo[1,2-a]pyridines are described.

Abstract: Process for the preparation of Flecainide, its pharmaceutically acceptable salts and important intermediates thereof that involves the use of the 2-halobenzoic acid and its derivatives as a starting material. The use of this process also allows for the synthesis of a novel intermediate useful in the production of Flecainide. This new process is an inexpensive and efficient process for the manufacture of these compounds.

Abstract: An agent comprising the benzoic acid of formula (I) wherein A, B, R6, R7 are carbocyclic ring, heterocyclic ring, etc.; R1 is hydroxy etc.; R2, R3, R4 are alkyl etc.; R5, D, E are alkylene, etc.; G is oxygen etc., as active ingredient. The compound of formula (I) is considered to be useful for the treatment and/or prophylaxis of bone diseases, cancer, systemic granuloma, immunological diseases, allergy, atopy, asthma, gumboil, gingivitis, periodontitis, neurocyte death, Alzheimer's diseases, lungs injury, pulmopathy, acute hepatitis, nephritis, myocardial ischemia, Kawasaki disease, ambustion, ulcerative colitis, Crohn's disease, multiple organ failure, sleeping disorder, platelet aggregation, etc.